News for ALONX Stock

Onxeo Announces its Financial Agenda for 2022 Summary of Onxeo’s Liquidity Contract With Kepler Cheuvreux Onxeo Appoints Julien Miara as New Interim CEO Onxeo: New Preclinical Data Confirm the Ability of AsiDNA™ to Tackle the Drug-Tolerant Persister Cells and Prevent Tumor Resistance in Several Combination Treatments Onxeo Continues to Strengthen its Board of Directors Onxeo Further strengthens its Board of Directors with two Seasoned Personalities from the Healthcare Sector